United States

Krystal Biotech Inc (KRYS.OQ)

KRYS.OQ on NASDAQ Stock Exchange Capital Market

21 Feb 2018
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Chart for


Krystal Biotech, Inc. is a gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. The Company has developed a Skin TARgeted Delivery platform, or STAR-D platform, that consists of a patent pending engineered viral vector based on herpes... (more)


Beta: --
Market Cap(Mil.): $88.76
Shares Outstanding(Mil.): 10.24
Dividend: --
Yield (%): --


  Industry Sector
P/E (TTM): -- 189.80 16.52
EPS (TTM): -- -- --
ROI: -- -0.65 36.19
ROE: -- -3.21 17.38

BRIEF-Krystal Biotech reports qtrly loss per share $1.26‍​

* Krystal Biotech reports that KB103 received clearance from RAC review and announces third quarter 2017 financial results

Nov 13 2017

BRIEF-Krystal Biotech says KB103 granted orphan drug designation by FDA

* Krystal Biotech’s KB103 granted orphan drug designation by the FDA to treat patients with dystrophic epidermolysis bullosa

Nov 07 2017

Earnings vs. Estimates